* GENOSAFE *
2003 - IDF
Évry
(near Paris)
www.genosafe.com Contract, Services
Key words: Bio-therapeutics, Drug evaluation
Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties
Clients: Pharmaceutical industry, Biotechs, Research labs
zuliani@genosafe.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Masquelier (Anne-Marie) [born 1953, M.D. endocrinology, also Managing Dir. Genethon, ex-MDS Pharma Services, Omnicare]
Sc.Dir.: Audit (Muriel) [Ph.D. Biology, ex-Genethon]
Fin.Dir.:
BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon]
Financers: AII (seed) | Turnover (M€) : 0.37 (2006)
Total funding (M€) : 3.5
Last funding (M€) : 3.5
Focus : Multiple
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2006 .11 | Financing : grant of 3.5 M€, by A2i (Oseo), coordinated by Mérieux Alliance, within ADNA project | DEBT | [3 years] |
| 2005 .06 | Nomination : Anne-Marie Masquelier, as CEO (plus, President, in 2006) | ORGN | [2 years] |
| 2003 .09 | Company founded by Genethon and AFM (Association Française pour les Myopathies, i.e. French Muscular Dystrophy Association) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
